Tue, 06/23/2009 - 16:58
China Biologic growing through acquisitions, R & D - CEO
by Karl Zhong
Colin Zhao, chief executive officer of China Biologic Products Inc., spoke to Interfax about his company's expansion strategy and development trends in China's blood product manufacturing industry.
Our emphasis is on improving our technology since the recent acquisitions have raised our production capacity to that of a leading player in China.
- Colin Zhao, chief executive officer of China Biologic Products Inc.
Shanghai. June 23. INTERFAX-CHINA - Despite strict Chinese government control over plasma collection and blood product manufacturing, China Biologic Products Inc. has successfully expanded its business through acquisitions and will continue to grow by investing in research and development, Colin Zhao, chief executive officer of the company, recently told Interfax.
